NCT04234724
Physiological Effects of ANGPTL3 Variants in Humans
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 13 versions: 10 with changes below, 3 re-verified with no change. See every version on ClinicalTrials.gov ↗
Stopped Trial status changed: Recruiting → Withdrawn Sponsor's reason: COVID pandemic Show 4 more changesShow less
- Enrollment target: estimated 50 to confirmed 0
- Eligibility criteria expanded, about 11 words
- Primary completion date changed from estimate of Jun 30, 2026 to Jun 30, 2021
- Site details revised
- Notable Primary and study completion dates: Jun 30, 2025 to Jun 30, 2026v12
- Notable Primary and study completion dates: Jan 1, 2024 to Jun 30, 2025v10
- Notable Trial status: Suspended to Recruiting
- Site details revised
- Minor Start date changed from estimate of Nov 1, 2020 to Dec 1, 2020v6
Show 4 earlier versionsHide 4 earlier versions
- Notable Start date: Sep 1, 2020 to Nov 1, 2020v5
- Notable Start date: Jul 1, 2020 to Sep 1, 2020v4
- Notable Start date: May 1, 2020 to Jul 1, 2020v3
- Stopped Trial status: Not Yet Recruiting to Suspended Sponsor's reason: Suspended due to COVID-19
- Study sites: 0 to 1
- Study First Submitted
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
The role of ANGPTL3 on lipid metabolism.
Timeframe: through study completion, an average of 13 weeks
The role of this protein on glucose metabolism.
Timeframe: through study completion, an average of 13 weeks
The role of ANPTL3 on fatty acids
Timeframe: through study completion, an average of 13 weeks
Arms and interventions
VariantExperimental
Volunteers with known ANGPTL3 variants
Non-variantOther
Healthy volunteers with no ANGPTL3 variants
Other: Kinetics test, oral fat tolerance test, and an oral glucose tolerance test.
Sites
1 site in 1 country
- University of PennsylvaniaPhiladelphia, Pennsylvania, United States